{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:52:17Z","timestamp":1785808337675,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40268-026-00545-w","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:28:47Z","timestamp":1779445727000},"page":"141-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ustekinumab in the Management of Perianal Fistulizing Crohn\u2019s Disease: Current Evidence and Practical Strategies"],"prefix":"10.1007","volume":"26","author":[{"given":"Bolin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3748\/wjg.v26.i14.1554","volume":"26","author":"XL Sun","year":"2020","unstructured":"Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab in perianal fistulizing Crohn\u2019s disease. World J Gastroenterol. 2020;26:1554\u201363. https:\/\/doi.org\/10.3748\/wjg.v26.i14.1554.","journal-title":"World J Gastroenterol"},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/mib.0000000000000315","volume":"21","author":"DA Schwartz","year":"2015","unstructured":"Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EM, et al. Guidelines for the multidisciplinary management of Crohn\u2019s perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21:723\u201330. https:\/\/doi.org\/10.1097\/mib.0000000000000315.","journal-title":"Inflamm Bowel Dis"},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.3748\/wjg.v24.i42.4821","volume":"24","author":"J Panes","year":"2018","unstructured":"Panes J, Reinisch W, Rupniewska E, Khan S, Forns J, Khalid JM, et al. Burden and outcomes for complex perianal fistulas in Crohn\u2019s disease: systematic review. World J Gastroenterol. 2018;24:4821\u201334. https:\/\/doi.org\/10.3748\/wjg.v24.i42.4821.","journal-title":"World J Gastroenterol"},{"key":"545_CR4","first-page":"2","volume":"8","author":"M Chen","year":"2024","unstructured":"Chen M, Chinese Society of Gastroenterology, Inflammatory Bowel Disease Quality Control Center of China. Chinese clinical practice guideline on the management of Crohn\u2019s disease (2023, Guangzhou). Chin J Inflamm Bowel Dis. 2024;8:2\u201332.","journal-title":"Chin J Inflamm Bowel Dis"},{"key":"545_CR5","doi-asserted-by":"publisher","unstructured":"Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association; Inflammatory Bowel Disease Quality Control Center of China. 2023 Chinese national clinical practice guideline on diagnosis and management of Crohn\u2019s disease. Chinese Medical Journal. 2024;137(14):1647\u201350. https:\/\/doi.org\/10.1097\/CM9.0000000000003221.","DOI":"10.1097\/CM9.0000000000003221"},{"key":"545_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160:2496\u2013508. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.022.","journal-title":"Gastroenterology"},{"key":"545_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jcag\/gwad023","volume":"7","author":"M Irani","year":"2024","unstructured":"Irani M, Abraham B. Choosing therapy for moderate to severe Crohn\u2019s disease. J Can Assoc Gastroenterol. 2024;7:1\u20138. https:\/\/doi.org\/10.1093\/jcag\/gwad023.","journal-title":"J Can Assoc Gastroenterol"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/nejm199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u2013405. https:\/\/doi.org\/10.1056\/nejm199905063401804.","journal-title":"N Engl J Med"},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u201385. https:\/\/doi.org\/10.1056\/NEJMoa030815.","journal-title":"N Engl J Med"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmb.2010.07.046","volume":"402","author":"J Luo","year":"2010","unstructured":"Luo J, Wu SJ, Lacy ER, Orlovsky Y, Baker A, Teplyakov A, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402:797\u2013812. https:\/\/doi.org\/10.1016\/j.jmb.2010.07.046.","journal-title":"J Mol Biol"},{"key":"545_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535\u201345. https:\/\/doi.org\/10.4161\/mabs.3.6.17815.","journal-title":"MAbs"},{"key":"545_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20:433\u201346. https:\/\/doi.org\/10.1038\/s41575-023-00768-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"545_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.044","author":"P Wils","year":"2026","unstructured":"Wils P, Nancey S, Messmer E, Bourreille A, Buisson A, Caillo L, et al. DOP007 Ustekinumab for fistulizing perianal Crohn\u2019s disease: week-48 results from the USTAP randomized placebo-controlledtrial. J Crohns Colitis. 2026. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf231.044.","journal-title":"J Crohns Colitis"},{"key":"545_CR15","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"key":"545_CR16","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/s0016-5085(17)30930-7","volume":"152","author":"BE Sands","year":"2017","unstructured":"Sands BE, Gasink C, Jacobstein D, Gao L-L, Johanns J, Colombel JF, et al. Fistula healing in pivotal studies of ustekinumab in Crohn\u2019s disease. Gastroenterology. 2017;152:S185. https:\/\/doi.org\/10.1016\/s0016-5085(17)30930-7.","journal-title":"Gastroenterology"},{"key":"545_CR17","doi-asserted-by":"publisher","first-page":"i460","DOI":"10.1093\/ecco-jcc\/jjab232.622","volume":"16","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, Panaccione R, Gasink C, Hoops T, Izanec JL, Ma T, et al. P495 perianal fistula closure in patients receiving ustekinumab: results from the SEAVUE and STARDUST trials. J Crohns Colitis. 2022;16:i460-i. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab232.622.","journal-title":"J Crohns Colitis"},{"key":"545_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/ecco-jcc\/jjac160","volume":"17","author":"T Sharma","year":"2023","unstructured":"Sharma T, Ma C, Sedano R, Hanzel J, McDonald C, Hogan M, et al. Placebo response rates in randomized controlled trials for perianal Crohn\u2019s disease: a systematic review and meta-analysis. J Crohns Colitis. 2023;17:644\u201358. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac160.","journal-title":"J Crohns Colitis"},{"key":"545_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","volume":"14","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, L\u00f6wenberg M, Dijkstra G, Oldenburg B, et al. Ustekinumab for Crohn\u2019s disease: results of the ICC Registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020;14:33\u201345. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz119.","journal-title":"J Crohns Colitis"},{"key":"545_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000702","volume":"8","author":"GM Godoy Brewer","year":"2021","unstructured":"Godoy Brewer GM, Salem G, Afzal MA, Limketkai BN, Haq Z, Tajamal M, et al. Ustekinumab is effective for perianal fistulising Crohn\u2019s disease: a real-world experience and systematic review with meta-analysis. BMJ Open Gastroenterol. 2021;8:e000702. https:\/\/doi.org\/10.1136\/bmjgast-2021-000702.","journal-title":"BMJ Open Gastroenterol"},{"key":"545_CR21","doi-asserted-by":"publisher","first-page":"i744","DOI":"10.1093\/ecco-jcc\/jjac190.0745","volume":"17","author":"Y Li","year":"2023","unstructured":"Li Y, Gu Y. P615 the safety and efficacy of ustekinumab combined with sphincter-preserving surgery for perianal fistulizing Crohn\u2019s disease: a single-center retrospective study. J Crohns Colitis. 2023;17:i744-6. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0745.","journal-title":"J Crohns Colitis"},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/apt.14016","volume":"45","author":"C Ma","year":"2017","unstructured":"Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232\u201343. https:\/\/doi.org\/10.1111\/apt.14016.","journal-title":"Aliment Pharmacol Ther"},{"key":"545_CR23","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","volume":"8","author":"U Kopylov","year":"2014","unstructured":"Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn\u2019s disease\u2014the McGill experience. J Crohns Colitis. 2014;8:1516\u201322. https:\/\/doi.org\/10.1016\/j.crohns.2014.06.005.","journal-title":"J Crohns Colitis"},{"key":"545_CR24","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.14309\/ajg.0000000000000810","volume":"115","author":"C Chapuis-Biron","year":"2020","unstructured":"Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, et al. Ustekinumab for perianal Crohn\u2019s disease: the BioLAP multicenter study from the GETAID. Am J Gastroenterol. 2020;115:1812\u201320. https:\/\/doi.org\/10.14309\/ajg.0000000000000810.","journal-title":"Am J Gastroenterol"},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.3730\/cma.j.cn112137-20230502-00707","volume":"103","author":"DL Zhang","year":"2023","unstructured":"Zhang DL, Shao XX, Hu DY, Lin DP, Wu H, Jiang Y. Analysis on the efficacy of dual vein induction therapy of ustekinumab in complex perianal fistulizing Crohn\u2019s disease. Natl Med J China. 2023;103:3301\u20136. https:\/\/doi.org\/10.3730\/cma.j.cn112137-20230502-00707.","journal-title":"Natl Med J China."},{"key":"545_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0837","volume":"18","author":"Q Chen","year":"2024","unstructured":"Chen Q, Gong Y, Yang F, Qiao L, Wang H, Zhang D, et al. Real-world long-term efficacy of ustekinumab in the treatment of perianal fistulizing Crohn\u2019s disease: results from a single-center retrospective study. J Crohns Colitis. 2024;18:i1336. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0837.","journal-title":"J Crohns Colitis"},{"key":"545_CR27","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/ibd\/izaa297","volume":"27","author":"M Attauabi","year":"2021","unstructured":"Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn disease: a double-center cohort study. Inflamm Bowel Dis. 2021;27:e37\u20138. https:\/\/doi.org\/10.1093\/ibd\/izaa297.","journal-title":"Inflamm Bowel Dis"},{"key":"545_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ecco-jcc\/jjad118","volume":"18","author":"HS Ten Bokkel","year":"2024","unstructured":"Ten Bokkel HS, Thomassen D, Steyerberg EW, Pauwels RWM, Casanova MJ, Bouguen G, et al. Discontinuation of anti-tumour necrosis factor therapy in patients with perianal fistulizing Crohn\u2019s disease: individual participant data meta-analysis of 309 patients from 12 studies. J Crohns Colitis. 2024;18:134\u201343. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad118.","journal-title":"J Crohns Colitis"},{"key":"545_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3760\/cma.j.cn311367-20230509-00226","volume":"43","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu L, Xie C, Pang X. Analysis of the short-term efficacy of ustekinumab as the first-line treatment for Crohn\u2019s disease. Chin J Dig. 2023;43:747\u201354. https:\/\/doi.org\/10.3760\/cma.j.cn311367-20230509-00226.","journal-title":"Chin J Dig"},{"key":"545_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3390\/jcm12030939","volume":"12","author":"J Yao","year":"2023","unstructured":"Yao J, Zhang H, Su T, Peng X, Zhao J, Liu T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn\u2019s disease: a retrospective real-world analysis. J Clin Med. 2023;12:939. https:\/\/doi.org\/10.3390\/jcm12030939.","journal-title":"J Clin Med"},{"key":"545_CR31","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1097\/mib.0000000000000842","volume":"22","author":"S Khorrami","year":"2016","unstructured":"Khorrami S, Ginard D, Mar\u00edn-Jim\u00e9nez I, Chaparro M, Sierra M, Aguas M, et al. Ustekinumab for the treatment of refractory Crohn\u2019s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662\u20139. https:\/\/doi.org\/10.1097\/mib.0000000000000842.","journal-title":"Inflamm Bowel Dis"},{"key":"545_CR32","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.dld.2025.08.091","volume":"57","author":"Q Chen","year":"2025","unstructured":"Chen Q, Li L, Wang C, Qiao L, Wu M, Zhu W, et al. Durable clinical and deep remission with ustekinumab in perianal fistulizing Crohn\u2019s disease: a 2-year retrospective real-world cohort study. Dig Liver Dis. 2025;57:2135\u201342. https:\/\/doi.org\/10.1016\/j.dld.2025.08.091.","journal-title":"Dig Liver Dis"},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/ajg.2009.509","volume":"104","author":"SC Ng","year":"2009","unstructured":"Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn\u2019s perineal fistulas. Am J Gastroenterol. 2009;104:2973\u201386. https:\/\/doi.org\/10.1038\/ajg.2009.509.","journal-title":"Am J Gastroenterol"},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/ibd.21940","volume":"18","author":"P Tozer","year":"2012","unstructured":"Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, et al. Long-term MRI-guided combined anti-TNF-\u03b1 and thiopurine therapy for Crohn\u02bcs perianal fistulas: Inflamm Bowel Dis. 2012;18:1825\u201334. https:\/\/doi.org\/10.1002\/ibd.21940.","journal-title":"Inflamm Bowel Dis"},{"key":"545_CR35","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","volume":"18","author":"M Adamina","year":"2024","unstructured":"Adamina M, Minozzi S, Warusavitarne J, Buskens CJ, Chaparro M, Verstockt B, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: surgical treatment. J Crohns Colitis. 2024;18:1556\u201382. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae089.","journal-title":"J Crohns Colitis"},{"key":"545_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cgh.2024.06.047","volume":"23","author":"LN Hanna","year":"2025","unstructured":"Hanna LN, Anandabaskaran S, Iqbal N, Geldof J, LeBlanc J-F, Dige A, et al. Perianal fistulizing Crohn\u2019s disease: utilizing the TOpClass classification in clinical practice to provide targeted individualized care. Clin Gastroenterol Hepatol. 2025;23:914\u201326. https:\/\/doi.org\/10.1016\/j.cgh.2024.06.047.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"545_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.rgmxen.2023.05.008","volume":"88","author":"CE Alc\u00e1ntara-Figueroa","year":"2023","unstructured":"Alc\u00e1ntara-Figueroa CE, Coronado-Rivera EF, Estela-V\u00e1squez EF, Calder\u00f3n-Cabrera DC, Alc\u00e1ntara-Asc\u00f3n RA. Ustekinumab and remission in perianal Crohn\u2019s disease: a case report. Rev Gastroenterol Mex. 2023;88:431\u20132. https:\/\/doi.org\/10.1016\/j.rgmxen.2023.05.008.","journal-title":"Rev Gastroenterol Mex"},{"key":"545_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae065","volume":"6","author":"HW Fiske","year":"2024","unstructured":"Fiske HW, Tse CS, Al-Bawardy B, Magavi P, Konijeti GG, Mao E, et al. Clinical course of isolated recurrent, persistent complex perianal fistulas without luminal Crohn\u2019s disease: a multicenter case series of 24 patients. Crohns Colitis 360. 2024;6:otae065. https:\/\/doi.org\/10.1093\/crocol\/otae065.","journal-title":"Crohns Colitis 360"},{"key":"545_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","volume":"63","author":"P Dewint","year":"2014","unstructured":"Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2013-304488.","journal-title":"Gut"},{"key":"545_CR40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","volume":"20","author":"RL West","year":"2004","unstructured":"West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn\u2019s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329\u201336. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02247.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"545_CR41","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.3748\/wjg.v23.i34.6197","volume":"23","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn\u2019s disease on anti-tumor necrosis factor therapy. World J Gastroenterol. 2017;23:6197\u2013200. https:\/\/doi.org\/10.3748\/wjg.v23.i34.6197.","journal-title":"World J Gastroenterol"},{"key":"545_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02963-5","volume":"23","author":"H Xu","year":"2023","unstructured":"Xu H, Xiao GZ, Zheng YH, Fu YJ, Zhong SL, Ren DL, et al. A magnetic resonance imaging-based decision-making tool for predicting complex anal fistulas healing in the early postoperative period. BMC Gastroenterol. 2023;23:372. https:\/\/doi.org\/10.1186\/s12876-023-02963-5.","journal-title":"BMC Gastroenterol"},{"key":"545_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","volume":"14","author":"P Wils","year":"2016","unstructured":"Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous Ustekinumab provides clinical benefit for two-thirds of patients with Crohn\u2019s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242-50.e1-2. https:\/\/doi.org\/10.1016\/j.cgh.2015.09.018.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"545_CR44","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.14309\/00000434-201710001-00651","volume":"112","author":"S Tsistrakis","year":"2017","unstructured":"Tsistrakis S, Oikonomou I. Real-life data on the use of ustekinumab for the treatment of fistulas in patients with Crohn\u2019s disease: 651. Am J Gastroenterol. 2017;112:S361.","journal-title":"Am J Gastroenterol"},{"key":"545_CR45","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/jgh.15390","volume":"36","author":"N Plevris","year":"2021","unstructured":"Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, et al. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn\u2019s disease: the Scottish ustekinumab cohort. J Gastroenterol Hepatol. 2021;36:2067\u201375. https:\/\/doi.org\/10.1111\/jgh.15390.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00545-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:43:46Z","timestamp":1785807826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-026-00545-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00545-w","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bolin Yang has no conflicts to disclose.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Note applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}